Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $11.00 at HC Wainwright

Y-mAbs Therapeutics (NASDAQ:YMAB) had its price objective lowered by HC Wainwright from $12.00 to $11.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 160.05% from the stock’s previous close. HC Wainwright also issued estimates for Y-mAbs Therapeutics’ FY2026 earnings at ($0.92) EPS.

A number of other brokerages have also recently issued reports on YMAB. Truist Financial dropped their price objective on Y-mAbs Therapeutics from $18.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, May 14th. Wedbush restated an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Morgan Stanley decreased their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a report on Wednesday, March 5th. Oppenheimer lowered their target price on shares of Y-mAbs Therapeutics from $21.00 to $20.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 14th. Finally, Bank of America lowered shares of Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price target for the company. in a research report on Tuesday, April 22nd. Two research analysts have rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $16.60.

Y-mAbs Therapeutics Stock Up 1.4%

NASDAQ YMAB opened at $4.23 on Monday. The firm has a market cap of $191.55 million, a P/E ratio of -7.83 and a beta of 0.53. The company’s 50 day moving average is $4.44 and its 200-day moving average is $6.91. Y-mAbs Therapeutics has a 12-month low of $3.55 and a 12-month high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.10. The business had revenue of $20.90 million for the quarter, compared to analysts’ expectations of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. Equities analysts expect that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Insider Transactions at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 10,810 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the transaction, the insider now owns 202,721 shares of the company’s stock, valued at approximately $1,060,230.83. This trade represents a 5.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 22.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of YMAB. Brooklyn Investment Group increased its stake in Y-mAbs Therapeutics by 4,563.8% in the 1st quarter. Brooklyn Investment Group now owns 5,923 shares of the company’s stock worth $26,000 after purchasing an additional 5,796 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Y-mAbs Therapeutics in the fourth quarter worth $46,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Y-mAbs Therapeutics in the first quarter worth $49,000. Corton Capital Inc. bought a new stake in Y-mAbs Therapeutics during the 1st quarter valued at $55,000. Finally, EntryPoint Capital LLC purchased a new stake in Y-mAbs Therapeutics during the 1st quarter valued at $56,000. 70.85% of the stock is owned by institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.